
-
Xilio Therapeutics NasdaqGS:XLO Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Location: 828 Winter Street, Waltham, MA, 02451, United States | Website: https://xiliotx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-31.3M
Cash
89.07M
Avg Qtr Burn
N/A
Short % of Float
4.88%
Insider Ownership
28.18%
Institutional Own.
40.58%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vilastobart (XTX101)+ atezolizumab Details Metastatic microsatellite stable colorectal cancer (MSS CRC) | Phase 1/2 Data readout | |
XTX301 Details Solid tumor/s | Phase 1 Data readout | |
XTX501 Details Solid tumor/s | IND Submission | |
XTX202 (monotherapy) Details Renal cell carcinoma, Melanoma | Failed Discontinued |